OM
PHVS icon

Opaleye Management’s Pharvaris PHVS Stock Holding History

Opaleye Management’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-79,837
Closed -$1.49M – 54
2021
Q2 		$1.49M Buy
+79,837
New +$1.81M 0.25% 44

Other funds holding PHVS

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Opaleye Management's PHVS Position: Q3 2021 in Review

Opaleye Management sold out of Pharvaris (PHVS) in Q3 2021, closing a stake of 79,837 shares — an estimated $1.49M sold.

Opaleye Management first reported a position in PHVS in Q2 2021 and held it in 1 quarter. The position peaked at $1.49M in Q2 2021. 25 funds tracked by Wall St. Rank hold PHVS as of Q3 2021.

  • Opaleye Management reported no remaining Pharvaris position as of Q3 2021 after selling out during the quarter.
  • Opaleye Management sold 79,837 Pharvaris shares in Q3 2021, an estimated $1.49M.
  • Opaleye Management first reported a position in Pharvaris in Q2 2021 and held it in 1 quarter.
  • Opaleye Management's Pharvaris position peaked at $1.49M in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Pharvaris as of Q3 2021.

Based on Opaleye Management's 13F filing for Q3 2021, filed 16 Nov 2021.